BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Receivables

Latest receivables for AEZS: $1.4M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.35M
↑ 38.69% YoYΔ $378000.00 vs prior year quarter

Peer average

Loading

COSCIENS Biopharma Receivables History

Loading

COSCIENS Biopharma vs. peers: Receivables Comparison

Loading

COSCIENS Biopharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

COSCIENS Biopharma (AEZS) FAQ

As of the most recent data (June 2024), AEZS shows a receivables of $1.4M. That compares with $980K in the prior-year period — up 38.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AEZS's receivables is now $1.4M (was $980K) — a 38.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether COSCIENS Biopharma is outperforming or lagging.

Tracking AEZS's receivables over time shows whether COSCIENS Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4M That compares with $980K in the prior-year period — up 38.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has COSCIENS Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.4M) with ownership activity and broader fundamentals.

COSCIENS Biopharma's receivables is $1.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.